Full-Time

SAP MDG Master Data Steward

Zeiss

Zeiss

1,001-5,000 employees

Manufactures high-precision optical instruments and devices

Compensation Overview

$94.2k - $117.8k/yr

+ Performance Bonus

Company Does Not Provide H1B Sponsorship

Dublin, CA, USA

Hybrid

Hybrid work arrangement in Dublin, California.

Bachelor's

Category
Data & Analytics (1)
Required Skills
SAP Products
Data Modeling
Data Governance
Data Analysis

Get referred to Zeiss

See people who can refer or advise you

Requirements
  • A bachelor's degree in business administration, information technology, or a related field is required.
  • A minimum of 3 to 5 years of experience in master data management, preferably within an SAP environment, is required.
  • Understanding of the business areas underlying owned data objects is required.
  • Experience serving as an initial point of contact for data-related questions is required.
  • Strong collaboration skills are required for working with cross-functional teams.
  • Ability to set up, maintain, and share documentation for data asset management is required.
  • Understanding of data cataloguing and data quality is required.
  • Knowledge of relevant data standards and formats is required.
  • Ability to evaluate data assets for conformance with data policies and processing conditions is required.
Responsibilities
  • Oversee the creation, maintenance, and deletion of master data records in SAP Master Data Governance.
  • Implement data governance policies and procedures to ensure data quality and integrity.
  • Conduct regular audits and data quality assessments to identify and resolve data discrepancies.
  • Monitor and manage defined data quality key performance indicators within the scope of responsibility.
  • Act as the contact person for data-related questions and assist employees in understanding data.
  • Document and maintain catalogue-relevant elements, including business descriptions, governance roles, data lineage, data quality, and data policies.
  • Collaborate with business stakeholders to define local data standards and governance processes and ensure compliance with established policies.
  • Educate local data users on best practices for data creation and management.
  • Supervise data-entry processes to enforce data integrity and quality and ensure that records meet organizational standards.
  • Ensure data privacy and compliance with CSOPs and standard operating procedures throughout the data lifecycle.
  • Work with information technology, finance, and operations teams to gather requirements and align master-data initiatives.
  • Grant data-access permissions and ensure that the appropriate people have access to required data.
Desired Qualifications
  • Knowledge of data governance frameworks and best practices.
  • Familiarity with data modeling concepts and data quality tools.
  • Certification in SAP Master Data Governance or related fields is a plus.
  • Experience with SAP Master Data Governance and data stewardship is highly desirable.

ZEISS is a global leader in optics and optoelectronics, serving medical professionals, industrial manufacturers, consumers, and the semiconductor industry. It designs and sells high-precision optical instruments, medical devices, semiconductor manufacturing equipment, and vision care products such as corrective lenses and eye-health services. Its products rely on advanced optics and imaging technologies to deliver accurate inspection, diagnosis, and manufacturing outcomes across healthcare, industrial quality control, consumer optics, and chip fabrication. What sets ZEISS apart is its breadth and depth: a long-standing scale in multiple markets, integrated solutions across optics, imaging, metrology, and precision engineering, and a commitment to sustainability in electricity use and carbon emissions. The company’s goal is to advance optics and optoelectronics by providing reliable, high-quality tools and services worldwide while operating in a sustainable way.

Company Size

1,001-5,000

Company Stage

Growth Equity (Non-Venture Capital)

Total Funding

$1.1B

Headquarters

Oberkochen, Germany

Founded

2001

Get referred to Zeiss

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • ZEISS won Mexico COFEPRIS approval in 2026 for ARTEVO 850 and MICOR 700.
  • ZEISS launched VisioGen commercially in the US at ASCRS 2026, expanding recurring software sales.
  • August 6, 2026 meditec nine-month results showed stable currency-adjusted revenue momentum.

What critics are saying

  • ZEISS announced June 9, 2026 cost cuts and expected job reductions across segments.
  • Carl Zeiss Meditec targets over €200 million annual savings through 2028/29, signaling pressure.
  • Medical Technology revenue fell 7% in first half fiscal 2025/26, exposing dependence on semiconductors.

What makes Zeiss unique

  • Foundation-owned ZEISS spans semiconductors, ophthalmology, and metrology under one capital structure.
  • ZEISS Semiconductor Manufacturing Technology grew 6% in first half fiscal 2025/26, driven by EUV optics.
  • ZEISS owns the IOLMaster, ARTEVO, and FORUM workflow stack across cataract care.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Paid Vacation

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

4%

2 year growth

4%
ZEISS
Aug 5th, 2026
ZEISS leads $2.5M investment in SeeTrue Technologies for miniaturised eye-tracking tech

ZEISS Ventures led a €2.2 million investment round in SeeTrue Technologies, a Finnish deep-tech company developing miniaturised eye-tracking technology. The funding will accelerate commercialisation of SeeTrue's ultra-low-power eye-sensing architecture for next-generation interfaces in smart optical systems and eyewear. SeeTrue's proprietary technology combines miniaturised sensing hardware with optimised embedded processing, enabling scalable eye-sensing capabilities with low power consumption and small hardware footprint. The technology supports gaze-based interaction and attention-aware computing across healthcare, industrial, and smart eyewear applications. The investment round includes participation from Superhero Capital and North Karelia Growth Fund, managed by Redstone Nordics. Founded in 2018 and based in Joensuu, Finland, SeeTrue develops ultra-miniature eye-tracking technology for medical optical systems, vision care, and smart wearables.

PR Newswire
Jun 11th, 2026
ZEISS completes early implantations of AT LUCIA toric 721P intraocular lens

ZEISS Medical Technology has announced successful early clinical implantations of its AT LUCIA toric 721P intraocular lens, designed to treat cataracts whilst correcting astigmatism. The company is conducting an early-access clinical trial with experienced surgeons across six European countries. The lens combines an aspheric bitoric optic with a patented non-constant aberration design on a fully preloaded, hydrophobic platform. Surgeons have reported positive early impressions, highlighting the lens's precision, stability and surgical handling. Currently CE marked, the AT LUCIA toric 721P will be showcased at the International Congress of German Ophthalmic Surgery in Nuremberg from 18–20 June 2026. The lens is expected to be commercially available in select European countries later this year.

ZEISS
May 28th, 2026
ZEISS invests in Maculaser to advance temperature-controlled retinal laser therapy

ZEISS Ventures has invested in Maculaser, a Finnish medtech company developing temperature-controlled retinal laser therapy, through a funding round co-led with M2care. The investment will support clinical development of the company's personalized treatment for retinal diseases. Founded in 2020 and based on research from Aalto University, Maculaser has developed patented technology that provides real-time temperature control during laser treatment. The non-damaging approach activates natural cellular defence mechanisms, targeting affected retinal areas early to delay or prevent progression of age-related macular degeneration and diabetic maculopathy. The technology aims to shift retinal care from managing late-stage damage to proactive vision preservation, offering an outpatient procedure that integrates into regular eye care. Maculaser plans to bring the treatment into clinical practice to benefit millions of patients worldwide.

PR Newswire
May 13th, 2026
ZEISS gains COFEPRIS approval for ARTEVO 850 and MICOR 700 ophthalmic surgical systems in Mexico

ZEISS Medical Technology has received approval from Mexico's COFEPRIS for two ophthalmic surgical devices: the ARTEVO 850 microscope and MICOR 700 lens removal device. Both technologies are compatible with ZEISS's latest cataract workflow systems. The ARTEVO 850 is a 3D heads-up ophthalmic microscope offering true colour imaging and a nearly 60% increase in depth of field. The MICOR 700 is the first handheld lens removal device with ultrasound-free operation, using ZEISS's non-ultrasonic lens extraction procedure to minimise risk to surrounding eye structures. The products will be showcased at the Mexican Congress of Ophthalmology in Monterrey from 30 May to 3 June 2026. ZEISS Medical Technology generated revenue of €2,066.1 million in fiscal year 2023/24.

Gridley Herald
Apr 29th, 2026
Hypervision Surgical raises $21.6M Series A for AI-assisted surgery platform

Hypervision Surgical, a UK-based pioneer in real-time hyperspectral imaging for surgery, has raised £17 million in an oversubscribed Series A round led by Heal Capital. Angelini Ventures participated alongside IP Group and Daycrest, with Angelini Ventures Managing Director Tanja Dowe joining the board. The King's College London spin-out has developed the Hyperspectral Intelligence platform, which combines hyperspectral sensing with AI-driven analytics to provide real-time, quantitative insights into tissue physiology during surgery. The technology captures information beyond what conventional surgical cameras can perceive, potentially improving intraoperative decision-making and reducing complications. The funding will support commercial deployment, clinical adoption and development of next-generation hyperspectral sensing technology. The company's HYPERSNAP system is certified in the UK and cleared by the US FDA.